Publication List of
Prof. Dr. med. Franz X. Vollenweider

Peer reviewed articles

Preller K, Burt JB, Ji JL, Schleifer C, Adkinson B, Stämpfli P, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A (2018): Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife (in press).

Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX (2018): Role of the 5-HT2A receptor in self- and other-initiated social interaction in LSD-induced states - a pharmacological fMRI study, J Neuoscience, 4;38(14):3603-3611.

Grimm O, Kraehenmann R, Preller KH, Seifritz E, Vollenweider FX (2018). Psilocybin modulates functional connectivity of the amygdala during emotional face Eur Neuropsychopharmacol. 28(6):691-700.

Kraehenmann R, Pokorny D, Aicher H. Preller KH, Pokorny T, Bosch O.G., Seifritz E., Vollenweider FX (2017): LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Front Pharmacol. 2017 Nov 8;8:814. doi: 10.3389/fphar.2017.00814. eCollection 2017.

Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX (2017): Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic tonal structure in music. Cereb Cortex 28(11):3939-3950.

Lewis C, Preller KH, Kraehenmann R, Michels L, Stämpfli P, Vollenweider FX (2017): Two dose investigation of the 5-HT-agonist psilocybin on regional and global cerebral blood flow. Neuroimage. 2017 Oct 1;159:70-78. doi:10.1016/j.neuroimage. 2017.07.020. Epub 2017 Jul 12.

Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX (2017): Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology, 234:2031-2046.

von Rotz R, Kometer Michael, Dornbierer Dario, Gertsch Jürg, Gachet Salomé M., Vollenweider FX, Seifritz Erich, Bosch Oliver G., Quednow Boris B., (2017): Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy, male volunteers, Psychopharmacology, 234(13):1957-1968

Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX (2017): Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol, 20:747-757

Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017): The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation, Curr Biol., 27(3):451-457

Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M,  Vollenweider FX (2016): Effects of serotonin 2A/1A receptor stimulation on social exclusion processing, PNAS, 113(18): 5119-5124

Kraehenmann R., Schmidt A, Friston K, Preller KH, Seifritz E, and Vollenweider FX (2016): The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage: Clinical 11, 53-60.

Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX (2016): Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur. J. Neuropsychopharmacology, 26(4):756-766

Kometer M, Pokorny T, Seifritz E, Vollenweider FX (2015): Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl) 232: 3663-3676

Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Muller F, Borgwardt S, Liechti ME (2015): Acute Effects of Lysergic Acid Diethylamide, Healthy Subjects. Biological Psychiatry 78: 544-553

Bernasconi F, Kometer M, Pokorny T, Seifritz E, Vollenweider FX (2015): The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. European Journal of Neuropsychopharmacology 25: 474-482

Krähenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2015): Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 78: 572-581

Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX (2014): Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry. Neuropsychopharmacology 39: 2485-2496

Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX (2014): Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin. Cereb Cortex, 24(12):3221-31

Ort A, Kometer M, Rohde J, Seifritz E, Vollenweider FX (2014) The role of GABAB receptors in human reinforcement learning. Eur. J. Neuropsychopharmacology 24: 1606-1614

Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013): Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.  J Neurosci. 19; 33(25):10544-51.

Schmidt A, Kometer M, Bachmann R, Seifritz E, and Vollenweider FX (2013): The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl); 225(1):227-39.

Schmidt A, Diaconescu AO, Kometer M, Friston KJ, Stephan KE, Vollenweider FX (2013) Modeling Ketamine Effects on Synaptic Plasticity During the Mismatch Negativity. Cerebral Cortex 23(10):2394-406.

Preller KH, Ingold N, Hulka LM, Vonmoos M, Jenni D, Baumgartner MR, Vollenweider FX, Quednow BB (2013): Increased Sensorimotor Gating in Recreational and Dependent Cocaine Users Is Modulated by Craving and Attention-Deficit/Hyperactivity Disorder Symptoms. Biol Psychiatry 73(3):225-34.

Holstein DH, Vollenweider FX, Geyer MA, Csomor PA, Belser N, Eich D (2013): Sensory and sensorimotor gating in adults suffering from attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res 205(1-2):117-26.

Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2012): Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37: 630-640.

Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX (2012): Mismatch Negativity Encoding of Prediction Errors Predicts S-ketamine-Induced Cognitive Impairments. Neuropsychopharmacology 37: 865-875

Kometer M, Bachmann R, Schmidt A, Seifritz E, Vollenweider FX (2012): Psilocybin biases facial recognition, goal-directed behavior, and mood state towards positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry: 72 (11):898-906.

Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX (2011): Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. NeuroImage 59: 3922-3932.

Studerus E, Kometer M, Hasler F, Vollenweider FX (2011): Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J.Psychopharmacology 25: 1434-1452.

Kometer M, Cahn, BR, Andel D, Carter OL, Vollenweider FX (2011): The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol. Psychiatry 69: 399-406

Holstein D H, Csomor PA, Geyer, MA, Hubert T, Brugger N, Vollenweider FX (2011): The effect of sertindole on sersory gating and cognition in healthy volunteers. J. Psychopharmacol.; 25(12):1600-13.

Hilti CC, Delko T, Orosz AT, Thomann K, Ludewig S, Geyer MA, Vollenweider FX, Feldon J, Cattapan-Ludewig K (2010): Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-Naive First-Episode Schizophrenia Patients. Neuropsychobiology 61: 79-86.

Holstein DH, Vollenweider FX, Jäncke L, Schopper C, Csomor PA (2010): P50 Suppression, Prepulse Inhibition, and Startle Reactivity in the Same Patient Cohort Suffering from Posttraumatic Stress Disorder. Journal of Affective Disorders 126(1-2): 188-197.

Roser P, Vollenweider FX, Kawohl W (2010): Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World Journal of Biological Psychiatry 11: 208-219.

Studerus E, Gamma A, Vollenweider FX (2010): Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE 5(8): e12412.

Vollenweider FX, Kometer M (2010): The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience 11: 642-651.

Csomor PA, Yee BK, Feldon J, Theodoridou A, Studerus E, Vollenweider FX (2009): Impaired prepulse inhibition and prepulse elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophrenia Bulletin 35: 244-255.

Hasler F, Kuznetsova OF, Krasikova RN, Cservenyak T, Quednow BB, Vollenweider FX, Ametamey SM, Westera G (2009): GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Appl. Radiat. Isot. 67: 598-601.

Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider FX (2009): Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology 23: 923-935.

Liechti ME, Hysek C, Vollenweider FX (2009): Interacting Cardiovascular Effects of Pindolol and MDMA (Ecstasy). Basic & Clinical Pharmacology & Toxicology (in press).

Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V (2009): Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry 66: 614-620.

Cattapan-Ludewig K, Ludewig S, Messerli N, Vollenweider FX, Seitz A, Feldon J, Paulus MP (2008): Decision-making dysregulation in first-episode schizophrenia. J. Nerv. Ment. Dis. 196: 157-160.

Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX (2008): Haloperidol differentially modulates prepulse inhibition and P50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 33: 497-512.

Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB (2008): On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav. Neurosci. 122: 885-900.

Geyer MA, Vollenweider FX (2008): Serotonin research: contributions to understanding psychoses. Trends Pharmacol.Sci. (TIPS) 29: 445-453.

Quednow BB, Csomor PA, Chmiel J, Beck T, Vollenweider FX (2008): Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. Int. J. Neuropsychopharmacol. 1-15.

Roser P, Vollenweider FX, Kawohl W (2008): Potential antipsychotic properties of central cannabinoid (CB(1)) receptor antagonists. World J. Biol. Psychiatry 1-12.

Wackermann J, Wittmann M, Hasler F, Vollenweider FX (2008): Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci. Lett. 435: 51-55.

Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007): Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 195: 415-424.

Vollenweider FX, Csomor PA., Knappe B, Geyer MA, Quednow BB (2007): The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32: 1876-1887.

Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007): Effects of psilocybin on time perception and temporal control of behaviour in humans. J. Psychopharmacol. 21: 50-64.

Csomor PA, Yee BK, Quednow BB, Stadler RR, Feldon R, Vollenweider FX (2006): The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus. Behav. Brain Res. 174: 143-150.

Vollenweider FX, Barro M, Csomor PA and Feldon J (2006): Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol. Psychiatry 60: 597-603.

Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005): Using psilocybin to investigate the relationship between attention, working memory and the serotonin1A&2A receptors. J Cognitive Neuroscience 17: 1497-1508.

Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX (2005): Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30: 1154-1162.

Cattapan-Ludewig K, Hilti CC, Ludewig S, Vollenweider FX, Feldon J (2005): Rapid visual information processing in schizophrenic patients: The impact of cognitive load and duration of stimulus presentation. Neuropsychobiology 52: 130-134.

Csomor PA, Vollenweider FX, Feldon J, Yee BK (2005): On the feasibility to detect and to quantify prepulse-elicited reaction in prepulse inhibition of the acoustic startle reflex in humans. Behavioural Brain Research 162: 256-263.

Gamma A, Brandeis D, Brandeis R, Vollenweider FX (2005): The P3 in “ecstasy“ ploydrug users during response inhibition and execution. J.Psychopharmacology 19: 504-512.

Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Ludewig K (2005): Information Processing Deficits and Cognitive dysfunctions in Panic Disorder. Journal of Psychiatry & Neuroscience 30(1): 37-43.

Vollenweider FX, Liechti M, Paulus MP (2005): MDMA affects both error-rate dependent and independent aspects of decision-making in two-choice prediction task.
J Psychopharmacology. 19: 366-374.

Carter O L,  Pettigrew J D, Burr D C, Alais D, Hasler F, Vollenweider FX (2004): Psilocybin impairs high-level but not low-level motion perception affects high-level but not low-level motion mechanisms in humans. NeuroReport 15:1947-1951.

Gamma A, Lehmann D, Frei E, Iwata K, Pascual-Marqui RD, Vollenweider FX (2004): Comparison of simultanously recorded [H215O]-Positron Emission Tomography (PET) and Low Resolution Brain Electromagnetic Tomography (LORETA) during cognitive and pharmacological activation. Human Brain Mapping 22:83-96.

Hasler F, Grimberg U, Benz M, Huber T, Vollenweider FX (2004): Acute psychological and physiological effects of psilocybin in healthy humans. A double-blind placebo-controlled dose-effect study. Psychopharmacology 172: 145-156.

Ludewig K, Geyer MA, Vollenweider FX (2003): Deficits in prepulse inhibition and habituation in never-medicated first-episode schizophrenia. Biol Psychiatry 54: 121-128.

Ludewig K, Ludewig S, Seitz A, Martina Obrist M, Geyer MA, Vollenweider FX (2003): The acoustic startle reflex and its modulation: Effects of age and gender in humans. Biol Psychology 63: 311-323.

Ludewig K, Paulus MP, Vollenweider FX (2003): Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. Psychiatry Res 119: 293-306.

Ludewig S, Paulus MP, Ludewig K, Vollenweider FX (2003): Decision-making strategies by panic disorder subjects are more sensitive to errors. J Affective Disorders 76:183-189.

Umbricht D, Vollenweider FX, Schmid L, Grübel.C, Skrabo A, Huber T, Koller R (2003): Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia. Neuropsychopharmacology 28: 170-181.

Hasler F, Bourquin D, Brenneisen R, Vollenweider FX (2002): Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man, J.Pharmaceutical and Biomedical Analysis 30: 331-339.

Leumann L, Feldon J, Vollenweider FX, Ludewig K (2002): Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenics. Biol Psychiatry 52: 729-739.

Ludewig K, Geyer MA, Etzensberger M, Vollenweider FX (2002): Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res 55: 129-137.

Ludewig K, Vollenweider FX (2002): Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. SWISS MED WKLY 132:159-165.

Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX (2002): Prepulse inhibition deficits in patients with panic disorder. Depression and Anxiety 15: 55-60.

Schönbächler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, Burger C, Berthold T, Brühlmeier M, Schubiger PA, Ametamey SM (2002): PET imaging of dopamine transporters in the human brain using [11C]-b-CPPIT, a cocaine derivative lacking the 2b-ester function. Nuc Med and Biol 29: 19-27.

Umbricht D, Koller R, Vollenweider FX, Schmid L (2002): Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51: 400-406.

Frei E, Gamma A, Pascual-Marqui RD, Lehmann D, Hell D, Vollenweider FX (2001): Localization of MDMA-induced brain activity in healthy volunteers using Low Resolution Brain Electromagnetic Tomography (LORETA). Hum Brain Mapping 14: 152-165.

Gamma A, Buck A, Berthold T, Vollenweider FX (2001): No difference in brain activation during cognitive performance between Ecstasy (MDMA) user and controls: A [H215O]-PET study. J Clin Psychopharmacol 21:66-71.

Leumann L, Sterchi D, Vollenweider FX, Ludewig K, Früh H (2001): A real world neuronal network approch to the primary acoustic circuit and prepulse inhibition. Brain Res Bul, 56:101-10.

Liechti ME, Gamma A, Vollenweider FX (2001): Gender differences in the subjective effects of MDMA, Psychopharmacology 154:161-168.

Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001): Effects of 3,4-Methylenedioxy-N-methylamphetamine (MDMA) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24:240-252.

Liechti ME, Vollenweider FX (2001): Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 16: 589-598.

Vollenweider FX, Jones RT, Baggott MJ (2001): Caveat Emptor: Editors Beware, Neuropsychopharmacology 24: 461-463.

Buck A, Gucker P, Schönbächler R, Arigoni M, Kneifel S, Vollenweider FX, Ametamey S, Burger C (2000): Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: Assessement of methods. J Cereb Blood Flow Metab 20:253-262.

Gamma A, Buck A, Berthold T, Vollenweider FX (2000): Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by (H215O)-PET in healthy humans. Neuropsychopharmacology 23: 388-395.

Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000): Mood state and brain electric activity in ecstasy users. NeuroReport 11:157-162.

Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000): Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521.

Liechti ME, Saur M, Gamma A, Hell D, Vollenweider FX (2000): Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23: 396-405.

Liechti ME, Vollenweider FX (2000): Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmaco, 10: 289-295.

Liechti ME, Vollenweider FX (2000): The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J. Psychopharmacology 14: 269-274.

Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000): Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Arch. Gen. Psychiatry 57: 1139-1147.

Vollenweider FX, Vontobel P, Leenders KL, Hell D (2000): Effects of S-ketamine on striatal dopamine release: a [11C] raclopride PET study of a model psychosis in humans. J Psych Res 34:35-43.

Vollenweider FX, Gamma A, Liechti ME, Huber T (1999): Is a single dose MDMA harmless? Neuropsychopharmacology 21:598-600.

Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999): Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology 143:365-372.

Vollenweider FX, Vontobel P, Hell D, Leenders KL (1999): 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: A PET study with [11C]raclopride. Neuropsychopharmacology 20:424-433.

Zessin J, Gucker P, Ametamey SM, Steinbach J, Brust P, Vollenweider FX, Johannsen B, Schubiger PA (1999): Efficient synthesis of enantiomerically pure thioesther precursors of [11C]McN-5652 from racemic McN-5652. J Label Comp and Radiopharm 42:1301-1312.

Ametamey S, Vollenweider FX, Patt J, Bourquin D, Hasler F, Beer HF, Schubiger PA (1998): 11C-Radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formation. J Label Comp and Radiophar, 41:585-594.

Vollenweider FX (1998): Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiat 31: 92-103.

Vollenweider FX, Antonini A, Leenders KL, Mathys K, Angst J (1998): Effects of high amphetamine doses on mood and cerebral glucose metabolism in normals using positron emission tomography (PET). Psychiatry Res Neuroimaging 83:149-162.

Vollenweider FX, Gamma A, Liechti ME, Huber T (1998): Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") on MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251.

Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D (1998): Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897-3902.

Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX (1997): Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72: 175-184.

Vollenweider FX, Antonini A, Leenders KL, Oye I, Hell D, Angst J (1997): Differential Psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers measured by FDG-PET. Eur Neuropsychopharmacol 7: 25-38.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997): Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372.

Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997): Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]-fluorodeoxyglocose (FDG). Eur Neuropsychopharmacol 7: 9-24.

Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ (1995): Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther Drug Monit 17: 95-100.

Vollenweider FX (1992): The use of psychotomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis [Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose]. SUCHT 38: 389-409.

Do KQ, Vollenweider FX, Zollinger M, Cuénod M (1991): Effect of climbing fiber deprivation on the K+-evoked release of endogenous adenosine from rat cerebellar slices. Eur J Neurosci 3: 201-208.

Vollenweider FX, Do KQ, Cuénod M (1990): Effect of climbing fiber deprivation on release of endogenous aspartate, glutamate and homocysteate in slices of rat cerebellar hemispheres and vermis. J Neurochem 54: 1533-1540.

 

Refereed  reviews

Preller KH, Vollenweider FX (2018) Phenomenology, structure and dynamic of psychedelic states, Curr Top Behav Neurosci. 2018;36:221-256.

Kometer M, Vollenweider FX (2018) Serotonergic hallucinogen-induced visual perceptual alterations. Curr Top Behav Neurosci. 2018;36:257-282.

Geyer MA, Nichols DE, Vollenweider FX (2009): Serotonin-Related Psychedelic Drugs. In: Squire LR (ed) Encyclopedia of Neuroscience. Academic Press, Oxford, 741-748.

Vollenweider FX (2008): Multidimeensional approach to sensory gating functions and cognition in humans. In: Gustafson R., Eberhard J. (eds) The diagnostic concept of schizophrenia: via the laboratory to the clinic. Production Espri, 33-44.

Hasler  F, Grimberg U, Vollenweider FX (2005): Einfluss von Psilocybin auf psychologische, kardiovaskuläre, neuroendokrine und blutchemische Parameter. Suchtforschung des BAG, 2002-03 1:101-113.

Vollenweider FX, Vollenweider-Scherpenhuyzen M F I (2003): Halluzinogene, Amphetamine und Entactogene. Therapeutische Umschau 60: 323-328.

Hasler F, Vollenweider FX (2005): Untersuchung der Rolle des Serotonin-1A-Rezeptors im psychopharmakologischen Wirkungsprofil von MDMA beim Menschen. Suchtforschung des BAG, 2002-03 1:87-100.

Vollenweider FX (2002): Neurocognitive effects and brain mechanisms of MDMA in humans. In Drogodependencias: Marco Juridico y Cuestiones Biomédicas. II Seminario International de Toxicologia y Legislación Sanitaria. Eds: Felix Gomez-Gallego and Fernando Bandrés Moya. Libero de Ponencias Y Comunicaciones, 29-33.

Vollenweider FX, Liechti M, Gamma A, Greer G, Geyer MA (2002): Physiological and psychological effects of MDMA in humans. J.Psychoactive Drugs 34: 171-184.

Vollenweider FX, Ludewig S (2002): Neurocognitive effects of MDMA: A summary of controlled human studies. Adiktologie 1 (Supp): 47-52.

Vollenweider FX (2001): Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience 3: 265-279.

Vollenweider FX, Geyer MA (2001): A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 56: 495-507.

Vollenweider FX, Geyer MA, Greer G (2001): Acute psychological and neurophysiological effects of MDMA in humans. Heffter Review Psych Res 2: 53-63.

Vollenweider-Scherpenhuyzen MFI, Vollenweider FX (2000): Emergency cases in drug abuse [Notfälle bei Drogenmissbrauch]. Der Internist 41: 886-898.

Vollenweider-Scherpenhuyzen MFI, Vollenweider FX (1999): Notfälle bei Drogenmissbrauch. Notfall & Rettungsmedizin 2: 518-531.

Vollenweider-Scherpenhuyzen MFI, Vollenweider FX (1998): Der Drogennotfall. Anaesthesist 47: 946-955.

Vollenweider FX (1997): MDMA-Forschungen am Menschen: Strategien und erste Ergebnisse. SUCHT, 35-43.

Vollenweider FX (1995): Positronen-Emissions-Tomographie (PET): Klinische Bedeutung und Perspektiven für die Psychiatrie. Nuclearmediziner 5: 309-317.

Vollenweider FX (1992): The use of psychotomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis [Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose]. SUCHT 38: 389-409.

Cuénod M, Audinat E, Do KQ, Gähwiler BH, Grandes P, Herrling P, Knöpfel T, Perschak H, Streit P, Vollenweider FX, Wieser HG (1990): Homocysteic acid as transmitter candidate in the mammalian brain and excitatory amino acids in epilepsy. Adv Exp Med Biol 268: 57-63.

Book contributions/proceedings

Behavioral Neurobiology of Psychedelic Drugs (2018). Series: Current Topics in Behavioral Neurosciences (Vol. 36). Halberstadt, Adam, Vollenweider, Franz X., Nichols, David E. (Eds.) Springer, Berlin, Heidelberg. eBook ISBN 978-3-662-55880-5

Vollenweider FX, Preller KH (2018): Neurobiologische Grundlagen der Wirkung von Psychedelika (423-436). In: von Heyden M., Jungaberle H., Majić T. (eds) Handbuch Psychoaktive Substanzen.Springer Reference Psychologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55125-3_70; Online ISBN 978-3-642-55125-3

Vollenweider FX (2008): Struktur und Neurobiologie der Halluzinogenerfahrung. In J. Jungaberle, P. Gasser, J. Weinhold & R. Verres (Eds.), Therapie mit psychoaktiven Substanzen. Praxis und Kritik der Psychotherapie mit LSD, Psilocybin und MDMA, Bern, Huber Verlag, 111-130.

Vollenweider MFI, Vollenweider FX (2004): Halluzinogene. Suchtberung in der Apotheke. Fahrmbacher-Lutz C. (Ed), Deutscher Apotheker Verlag Stuttgard, 200-218.

Gamma A, Lehmann D, Frei E, Pascual-Marqui RD, Vollenweider FX (2002): The relationship between co-recorded [H215O]-PET and EEG functional tomography (LORETA) before and during pharmacological activation, Excerpta Medica International Congress Series, 1232 (2002) 247-251.

Vollenweider FX, Ludewig K, Vollenweider MFI (2002): Schizophrenie – Auf der Spur eines Rätsels. Gehirn und Geist, Spektrum der Wissenschaft, 4: 36-42.

Gamma A., Liechti ME, Vollenweider FX (2001): Giving MDMA to Human Volunteers in Switzerland. In Holland, J (Ed.), Ecstasy: The complete guide. Rochester, Park Street Press, 327-337.

Vollenweider FX (2001): Vom Zauberpilz zur Hirnforschung, unijournal Universität Zürich, 1: 7.

Vollenweider FX (2000): Halluzinogene und Gehirn: Beeinflussung der Hirnaktivität durch Halluzinogene. In Georg-Friedrich-Götz Stiftung (Ed.), Festschrift aus Anlass der Verleihung des Georg-Friederich-Götz-Preises Medizinische Fakultät der Universität Zürich, 2000, 51-75.

Vollenweider FX, Frei E, Gamma A (2000): Lokalisation MDMA-induzierter hirnelektrischer Aktivität bei gesunden Probanden mittels Low Resolution Brain Electromagnetic Tomoraphy (LORETA). In Rihs-Middle M (ed), Suchtforschung des BAG. Bern, BAG, 6-14.

Vollenweider FX, Gamma A, Vollenweider-Scherpenhuyzen MFI (1999): Neuronal correlates of hallucinogen-induced altered states of consciousness. In Hameroff SR, Kaszniak AW, Chalmers DJ (eds), Towards a Science of Consciousness. The Third Tucson Discussion and Debates. Cambridge, MIT Press, 99-109.

Vollenweider FX (1998): Beziehung zwischen Hirnaktivitätsmustern (PET) und Dimensionen veränderter Bewusstseinszustände. In Verres R, Leuner H, Dittrich A (eds), Welten des Bewusstseins. Multidisziplinäre  Entwürfe. 1 Berlin, Verlag für Wissenschaft und Bildung (VWB), 111-126.

Vollenweider FX (1998): Neue Aspekte der PET-und SPECT-Forschung: Metabolische Korrelate psychotischer Störungen bei Schizophrenen und Modell-Psychosen. In Hinterhuber H, Fleischhacker WW (eds), Biologische Grundlagen der Schizophrenien. 1 140-160.

Vollenweider FX (1998): Recent advances and concepts in the search for biological correlates of hallucinogen-induced altered states of consciousness. The Heffter Review Psych Res, 1: 21-32.

Vollenweider FX (1996): Perspektiven der Bewusstseinsforschung mit Halluzinogenen. In Liggenstorfer R, Rätsch C (eds), Maria Sabina - Botin der heiligen Pilze. Vom traditionellen Schamanentum zur weltweiten Pilzkultur. 1 Freiburg, Nachtschattenverlag, 203-210.

Vollenweider FX (1994): Evidence for a cortical-subcortical dysbalance of sensory information processing during altered states of consciousness using PET and FDG. In Pletscher A, Ladewig D (eds), 50 Years of LSD: State of the Art and Perspectives of Hallucinogens. 1 London, Parthenon Publishing, 67-86.

Vollenweider FX (1994): Kortiko-Subkortikale Dysbalance während Ketamin- und Psilocybin- induzierten Bewusstseinszuständen. In Dittrich A, Hofmann A, Leuner H (eds), Welten des Bewusstseins. Band 3: Experimentelle Psychologie, Neurobiologie und Chemie. 1 Berlin, VWB - Verlag für Wissenschaft und Bildung, 25-43.

Vollenweider FX, Leenders KL, Angst J (1994): Hyperfrontalität während Ketamin- und Psilocybin-induzierten Modell-Psychosen: Eine PET-Studie mit gesunden Probanden. In Peters UH, Schifferdecker M, Krahl A (eds), 150 Jahre Psychiatrie. Eine vielgestaltige Psychiatrie für die Welt von Morgen. Köln, Martini-Verlag, 479-484.

Vollenweider FX, Antonini A, Scharfetter C, Angst J, Leenders KL (1993): Zerebraler Energiemetabolismus während akut induzierter Ketamin-Modell-Psychose bei gesunden Probanden, gemessen mittels PET (Positronen-Emissions-Tomographie) und [18F]-Fluorodeoxyglukose. In Baumann P (ed), Biologische Psychiatrie der Gegenwart. 1 Wien, Springer-Verlag, 497-499.

Vollenweider FX, Vollenweider MFI (1993): Halluzinogene: Eine Droge berauscht die Wissenschaft. Psychologie Heute 5: 30-36.

Vollenweider FX (1992): Der Einsatz von PET (Positronen-Emissions-Tomographie) zum Studium neuronaler Aktivität während veränderter Bewusstseinszustände. In Leuner H, Schlichting M (eds), Jahrbuch des Europäischen Collegiums für Bewusstseinsstudien 1992. 1 Berlin, VWB - Verlag für Wissenschaft und Bildung, 33-52.

Cuénod M, Do KQ, Vollenweider FX, Klein A, Streit P (1988): The puzzle of the transmitters in the climbing fibers. In Strata P (ed), Experimental Brain Research Series (Symposium on "The olivocerebellar system in motor control"). Springer, Berlin.

Streit P, Do KQ, Vollenweider FX, Grandes P, Liu C-J, Matute C, Cuénod M (1988): Localisation and Release of Excitatory Amino Acids. In AnonymousFrontiers in Excitatory Amino Acid Research. Alan R. Liss, Inc., 101-108.